Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …

Immune checkpoint molecules are promising anticancer targets, among which therapeutic
antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment …

Nivolumab, an anti–programmed death-1 (PD-1) monoclonal antibody, showed promising
activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase 1 study. We …

Background PD-L1 enhanced the tumorigenesis and immune escape abilities of cancers.
The upstream mechanisms of PD-L1 in regulating tumorigenesis and immune escape of …

Abstract PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types
of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most …

Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses.
Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response …

Evading immune eradication is a prerequisite for neoplastic progression and one of the
hallmarks of cancer. Here, we review the different immune escape strategies of lymphoma …

Immune checkpoint blockade therapeutics, notably antibodies targeting the programmed
death 1 (PD-1) receptor and its PD-L1 and PD-L2 ligands, are currently revolutionizing the …

Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with
relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome …

Mantle cell lymphoma (MCL), a rare and aggressive B-cell non-Hodgkin lymphoma, mainly
develops in the lymph node (LN) and creates a protective and immunosuppressive niche …